Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Zhenghua Lv, Xiuxiu Liu, Shengli Zhou, Xianfang Liu, Peihang Jing, Wei Xu, Shifeng Kan, Zhancheng Zhang
Publikováno v:
International Journal of Oncology
Cisplatin is a widely used platinum-based chemotherapeutic agent for hypopharyngeal squamous cell carcinoma (HSCC). However, resistance to cisplatin limits its use for the treatment of HSCC, and the underlying molecular mechanism requires further inv
Publikováno v:
International Journal of Molecular Medicine.
In gastric cancer, >15% of cases are associated with the amplification of human epidermal growth factor receptor 2 (HER2), which leads to poor clinical outcomes. Lapatinib, a potent ATP‑competitive inhibitor, is a small, orally active molecule, whi
Publikováno v:
Molecular Medicine Reports.
The RAF/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK (RAF/MEK/ERK) signaling cascade serves a prominent role in hepatocellular carcinoma (HCC) proliferation. Sorafenib (BAY 43‑9006) is a poten
Publikováno v:
Molecular Medicine Reports. 11:4333-4340
The aim of this study was to investigate the effect of the tumor‑targeting recombinant human tumor necrosis factor (rhTNF)‑α fusion protein mediated by urokinase on Sl80 tumor‑bearing mice, as well as to explore its mechanisms of action. Furth
Autor:
Nozomu Tanaka, Kei Oguchi, Kazuki Sakamoto, Hiroyuki Okabe, Keiji Ishida, Fumio Nakagawa, Yukari Yamada, Hideki Nagase, Tatsushi Yokogawa, Akiko Osada, Keisuke Yamamura, Akio Fujioka, Hiromi Kazuno, Kenichi Matsuo
Publikováno v:
Oncology Reports
TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI). The compound improves overall survival of colorectal cancer (CRC) patients who are insensitive to standard chemotherapies. FTD possess
Autor:
Juan Wang, Zhi-Yu Wang, Peng-Hui Shi, Yuehua Zhang, Xing Li, Shenghu Guo, Xin Shu, Baoen Shan, Yan Ding, Lianping Xing
Publikováno v:
International Journal of Oncology. 45:1469-1478
Prostate cancer is the most common malignancy diagnosed in males, and bone metastases remain a significant source of morbidity and mortality in this population. Ubiquitin ligase E3s and proteasomes were thought to play essential roles in the developm
Publikováno v:
International Journal of Oncology. 45:919-928
Drug development for castration resistant prostate cancer (CRPC) is challenging, since this cancer is still associated with high mortality and limited therapeutic options. In 2004, docetaxel became the first-line chemotherapy for CRPC improving survi
Autor:
Fenfei Zou, Chie Soeno, Rintaro Noro, Yuji Minegishi, Masaru Matsumoto, Haruka Uesaka, Susumu Takeuchi, Masahiro Seike, Nobuhiko Nishijima, Teppei Sugano, Akihiko Gemma, Kaoru Kubota
Publikováno v:
International Journal of Oncology. 44:1886-1894
Pemetrexed (PEM) is currently recommended as one of the standard anticancer drugs for malignant pleural mesothelioma (MPM). However, the mechanism of the sensitivity of MPM to PEM remains unclear. We analyzed the antitumor effects of PEM in six MPM c
Autor:
Bang-Ce Ye, Wenmin Hou, Kurtis E. Bachman, Xuehua Zhu, Xia Qin, Li Liu, Crystal Ying Qin Zang, Hui Wang, Maogui Fei, Joel Greshock, Ping Liu, Pingkuan Zhang, Hanlim Moon
Publikováno v:
Oncology Reports. 30:707-714
Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains. To explore the potential utility of lapatinib for the treatment of esophageal squamous cell carcinoma (ESCC), we
Autor:
Atanasio Pandiella, Glòria Oliveras, Clara Panosa, Rafael de Llorens, Dolors Carrion-Salip, Anna Massaguer, Teresa Puig, Javier A. Menendez
Publikováno v:
© International Journal of Oncology, 2012, vol. 41, núm. 3, p. 1128-1138
Articles publicats (D-B)
DUGiDocs – Universitat de Girona
instname
Recercat. Dipósit de la Recerca de Catalunya
Digital.CSIC. Repositorio Institucional del CSIC
Articles publicats (D-B)
DUGiDocs – Universitat de Girona
instname
Recercat. Dipósit de la Recerca de Catalunya
Digital.CSIC. Repositorio Institucional del CSIC
et al.
The deregulation of the epidermal growth factor receptor (EGFR) pathway plays a major role in the pathogenesis of prostate cancer (PCa). However, therapies targeting EGFR have demonstrated limited effectiveness in PCa. A potential mechani
The deregulation of the epidermal growth factor receptor (EGFR) pathway plays a major role in the pathogenesis of prostate cancer (PCa). However, therapies targeting EGFR have demonstrated limited effectiveness in PCa. A potential mechani